{"id":3703,"date":"2025-03-31T18:11:47","date_gmt":"2025-03-31T18:11:47","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/atazanavir-txt\/"},"modified":"2025-03-31T18:11:47","modified_gmt":"2025-03-31T18:11:47","slug":"atazanavir-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/atazanavir-txt\/","title":{"rendered":"Atazanavir.txt"},"content":{"rendered":"

Atazanavir<\/h1>\n

CLINICAL USE <\/H3>
\nProtease inhibitor:<\/p>\n
  • HIV infection, in combination with other\n

    antiretroviral drugs
    \n

    DOSE IN NORMAL RENAL FUNCTION <\/H3>
    \n300 mg once daily with ritonavir 100 mg once
    \ndaily
    \n

    PHARMACOKINETICS <\/H3>
    \n
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \n802.9 (as sulphate)\n<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \n86\n<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp :
    \n7\n<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :
    \nNo data\n<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :
    \n7\/no data
    \n

    DOSE IN RENAL IMPAIRMENT <\/H3>
    \n

    GFR (mL\/MIN)<\/H4>
    \n
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
    \n
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
    \n
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp :
    \nDose as in normal renal function
    \n

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
    \n
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:
    \nUnlikely to be dialysed. Dose as in
    \nnormal renal function<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \nUnlikely to be dialysed. Dose as in
    \nnormal renal function
    \n
  • HDF\/high flux &nbsp :
    \nUnlikely to be dialysed. Dose as in
    \nnormal renal function
    \n
  • CAV\/VVHD &nbsp &nbsp &nbsp:
    \nUnknown dialysability. Dose as in
    \nnormal renal function
    \n

    IMPORTANT DRUG INTERACTIONS <\/H3>
    \nPotentially hazardous interactions with other drugs<\/p>\n
  • Anti-arrhythmics: possibly increased\n

    plasma levels of amiodarone and lidocaine<\/p>\n

  • Antibacterials: concentration of both\n

    drugs increased when given with
    \nclarithromycin; rifabutin concentration
    \nincreased \u2013 reduce dose of rifabutin;
    \nrifampicin reduces atazanavir
    \nconcentration \u2013 avoid concomitant use;
    \navoid concomitant use with telithromycin
    \nin severe renal and hepatic impairment<\/p>\n

  • Antidepressants: concentration reduced by\n

    St John\u2019s wort \u2013 avoid concomitant use<\/p>\n

  • Antimalarials: avoid concomitant\n

    administration with artemether\/
    \nlumefantrine<\/p>\n

  • Antipsychotics: possibly inhibits\n

    metabolism of aripiprazole \u2013 reduce
    \ndose of aripiprazole; possibly increased
    \nconcentration of pimozide \u2013 avoid
    \nconcomitant use<\/p>\n

  • Antivirals: concentration reduced by\n

    efavirenz \u2013increase dose of atazanavir;
    \nconcentration possibly reduced by
    \nnevirapine \u2013 avoid concomitant use;
    \nsaquinavir concentration increased;
    \nconcentration reduced by tenofovir and
    \ntenofovir concentration possibly increased;
    \navoid concomitant use with indinavir
    \nC<\/p>\n

  • alcium-channel blockers: concentration\n

    of diltiazem increased \u2013 reduce dose of
    \ndiltiazem; possibly increased verapamil
    \nconcentration<\/p>\n

  • Ciclosporin: possibly increased\n

    concentration of ciclosporin<\/p>\n

  • Cytotoxics: possibly inhibits metabolism of\n

    irinotecan \u2013 increased risk of toxicity<\/p>\n

  • Ergot alkaloids: possibly increased\n

    concentration of ergot alkaloids \u2013 avoid
    \nconcomitant use
    \nOestrogens: increased concentration of <\/p>\n

    ethinylestradiol \u2013 avoid concomitant use
    \nSildenafil: possibly increased side effects <\/p>\n

    of sildenafil<\/p>\n

  • Sirolimus: possibly increased\n

    concentration of sirolimus
    \nStatins: avoid concomitant use with <\/p>\n

    simvastatin \u2013 increased risk of myopathy;
    \npossibly increased risk of myopathy with
    \natorvastatin
    \nt is not licensed for use by anyone else.<\/p>\n

  • Tacrolimus: possibly increased\n

    concentration of tacrolimus<\/p>\n

  • Ulcer-healing drugs: concentration\n

    significantly reduced by omeprazole and
    \nesomeprazole and possibly other proton
    \npump inhibitors \u2013 avoid concomitant
    \nuse; concentration possibly reduced by
    \nhistamine H2 antagonists
    \n

    ADMINISTRATION <\/H3>
    \n

    Reconstition<\/H4>
    \n\u2013
    \n

    Route <\/H4>
    \nOral<\/p>\n

    Rate of Administration <\/H4>
    \nTake with food<\/p>\n

    Comments<\/H4>
    \nTake didanosine 2 hours after atazanavir if <\/p>\n

    used in combination<\/p>\n","protected":false},"excerpt":{"rendered":"

    Atazanavir CLINICAL USE Protease inhibitor: HIV infection, in combination with<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3703","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3703","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3703"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3703\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3703"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3703"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3703"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}